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Abstract
Background: Gliosarcoma is one of the most common malignant brain tumors, and anti-angiogenesis is a promising
approach for the treatment of gliosarcoma. However, chemotherapy is obstructed by the physical obstacle formed by the
blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB). Honokiol has been known to possess potent
activities in the central nervous system diseases, and anti-angiogenic and anti-tumor properties. Here, we hypothesized that
honokiol could cross the BBB and BCSFB for the treatment of gliosarcoma.
Methodologies: We first evaluated the abilities of honokiol to cross the BBB and BCSFB by measuring the penetration of
honokiol into brain and blood-cerebrospinal fluid, and compared the honokiol amount taken up by brain with that by other
tissues. Then we investigated the effect of honokiol on the growth inhibition of rat 9L gliosarcoma cells and human U251
glioma cells in vitro. Finally we established rat 9L intracerebral gliosarcoma model in Fisher 344 rats and human U251
xenograft glioma model in nude mice to investigate the anti-tumor activity.
Principal Findings: We showed for the first time that honokiol could effectively cross BBB and BCSFB. The ratios of brain/
plasma concentration were respectively 1.29, 2.54, 2.56 and 2.72 at 5, 30, 60 and 120 min. And about 10% of honokiol in
plasma crossed BCSFB into cerebrospinal fluid (CSF). In vitro, honokiol produced dose-dependent inhibition of the growth
of rat 9L gliosarcoma cells and human U251 glioma cells with IC50 of 15.61 mg/mL and 16.38 mg/mL, respectively. In vivo,
treatment with 20 mg/kg body weight of honokiol (honokiol was given twice per week for 3 weeks by intravenous
injection) resulted in significant reduction of tumor volume (112.70610.16 mm
3) compared with vehicle group
(238.63619.69 mm
3, P=0.000), with 52.77% inhibiting rate in rat 9L intracerebral gliosarcoma model, and
(1450.836348.36 mm
3) compared with vehicle group (2914.176780.52 mm
3, P=0.002), with 50.21% inhibiting rate in
human U251 xenograft glioma model. Honokiol also significantly improved the survival over vehicle group in the two
models (P,0.05).
Conclusions/Significance: This study provided the first evidence that honokiol could effectively cross BBB and BCSFB and
inhibit brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. It
suggested a significant strategy for offering a potential new therapy for the treatment of gliosarcoma.
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Introduction
Malignant gliomas account for approximately 70% of the
22,500 new cases of malignant primary brain tumor that are
diagnosed in adults in the United States each year [1].
Gliosarcoma comprises about 2% of all glioblastomas and is a
very aggressive tumor [2–5]. Despite optimal treatment, the
median survival for patients with gliosarcoma is less than 12
months. Anti-angiogenesis is a promising approach for the
treatment of gliosarcoma [6–9]. However, the blood-brain barrier
(BBB) and blood-cerebrospinal fluid barrier (BCSFB) hampered
the effects of both conventional and targeted therapies. Therefore,
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must cross the BBB and BCSFB. The BBB and BCSFB compose
of capillary endothelial cells connected by tight junctions. Their
main function is to be a physical and active barriers to restrict and
regulate the penetration of compounds into and out from the brain
to maintain brain homeostasis. The surface area of the BBB has
been estimated to be 5000-fold greater than that of the BCSFB
[10]. Therefore, the BBB is considered to be the major route for
the uptake of endogenous and exogenous ligands into central
nervous system.
Honokiol (39,5-di-2-propenyl-1,19-biphenyl-2,49-diol), as a nat-
ural compound, has been isolated and identified from the stem
bark of Magnolia officinalis Rehd. et Wils. (Houpu in Chinese).
Honokiol has long been known to possess activities against
oxidation [11], anxiety [12–15], depression [16], and in
prevention and protection the brain from damage [17] in the
central nervous system. Recent studies have shown that honokiol
had also extensive anti-tumor efficacy in vitro and in vivo [18–21],
especially, it exhibited strong anti-angiogenesis effects [22,23]. In
addition, honokiol was a potential strategy to overcome immu-
noresistance in glioma [24]. However, few studies, up to date, were
reported on its abilities to cross BBB and BCSFB and the effects
for the treatment of gliosarcoma in vivo. In this study, we
hypothesized that honokiol might cross BBB and BCSFB, and
exhibit its anti-tumor activity in rat 9L intracerebral gliosarcoma
model and human U251 xenograft glioma model in vivo.
Two of several methods for assessing BBB penetration in vivo
are widely used: determinations of brain/plasma ratio and
measurement of the permeability6surface area product (PS)
[25]. In our study, the methods determining the ratio of brain/
plasma concentrations and the concentration of cerebrospinal fluid
were used to evaluate whether honokiol could cross BBB and
BCSFB. Then, intracerebral rat gliosarcoma model and xenograft
human glioma model were established to evaluate the efficacy of
honokiol via intravenous administration.
Results
Validation of HPLC Method and Honokiol Amount in
Plasma
A HPLC method was developed to measure the amount in
plasma, brain, cerebrospinal fluid and other tissues. The retention
times of honokiol and internal standard were about 6.5 and
9.5 min by HPLC analysis, respectively. Linearity was determined
using freshly prepared spiked plasma, CSF and tissues homogenate
samples. The mean equations for the calibration curves of
honokiol were y=0.98x+0.63 (n=5) with a correlation coefficients
of 0.9989 in plasma, y=0.53x+0.76 (n=5) with a correlation
coefficients of 0.9992 in CSF, y=0.31x+0.19 (n=5) with a
correlation coefficients of 0.9991 in brain, y=0.43x20.68 (n=5)
with a correlation coefficients of 0.9996 in heart, y=0.26x+0.35
(n=5) with a correlation coefficients of 0.9986 in liver,
y=0.38x20.56 (n=5) with a correlation coefficients of 0.9985
in spleen, y=0.41x+0.62 (n=5) with a correlation coefficients of
0.9986 in lung and y=0.36x+0.58 (n=5) with a correlation
coefficients of 0.9991 in kidney. The recoveries in plasma, CSF,
brain and other tissues were between 86.23% and 104.62%. The
intra-day RSD and inter-day were both less than 14.28%.
The mean plasma concentration-time curve of honokiol in rat
plasma following intravenous administration of 20 mg/kg was
shown in Figure 1. Each point with bar represented the
mean+SD (n=6). The pharmacokinetic parameters were present-
ed in Table 1.
BCSFB Penetration and CSF Distribution of Honokiol
Table 2 displayed the amount of honokiol in CSF and the
percentages of Ccsf/Cp (cerebrospinal fluid/plasma mean concen-
tration percentages) at four time points. The results confirmed that
honokiol could cross BCSFB into CSF and about 10% of its
amount in plasma could do it. For example, 11.39% [(1.059 mg/
mL/9.30 mg/mL)6100] of honokiol amount in plasma crossed
BCSFB into CSF at 5 min post administration, 24.98%
[(0.602 mg/mL/2.41 mg/mL)6100] of honokiol amount in plasma
crossed BCSFB into CSF at 30 min, 9.05% [(0.095 mg/mL/
1.05 mg/mL)6100] of honokiol amount in plasma crossed BCSFB
into CSF at 60 min, and after 120 min (about third half-life time,
T1/2=41.37 min), the percentage still reached 9.81 [(0.053 mg/
mL/0.54 mg/mL)6100].
Assessment of BBB Penetration (Brain/Plasma Ratio) and
Brain Distribution of Honokiol
Since the BBB is considered to be the major route for the uptake
of endogenous and exogenous ligands into central nervous system,
we investigated intensively the BBB penetration. Table 2 showed
the amount of honokiol in brain. The results revealed that
honokiol could be easy to penetrate through the BBB into brain.
Honokiol was detectable in rat brain and expeditiously achieved
the peak value of 11.9761.09 mg/g at 5 min post administration,
and still kept a high concentration of 1.4760.38 mg/g at 120 min
(about third half-life time). The ratios of Cb/Cp (brain/plasma
concentration ratios), an important indicator to evaluate the brain
uptake index [10,25], were used to further evaluate BBB
penetration of honokiol. The Cb/Cp represented the ratio between
the concentration in brain and the concentration in plasma at the
same time point. Generally, the higher the ratio is, the greater the
ability to cross the BBB is. As showed in Table 3, the ratios of Cb/
Cp at 5 min, 30 min, 60 min and 120 min were respectively 1.29,
2.54, 2.56 and 2.72, suggesting that honokiol was easy to enter the
brain and had a good BBB penetration.
Comparison of Honokiol Distribution
The percentage of honokiol amount in all samples including
plasma, brain and other tissues at 30 min after administration was
Figure 1. Mean plasma concentration-time curve of honokiol in
rat plasma (The data from 0 min was omitted).
doi:10.1371/journal.pone.0018490.g001
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Percentage~(Msample=Minjection)|100~
(CsampleVtotal=MdoseW)|100:
Where Msample was the amount of honokiol (mg) in sample;
Minjection was the injection amount of honokiol (mg); Csample was
the concentration of honokiol (mg/mL) in plasma or (mg/g) in
tissues; Vtotal was the total volume of blood in animals which was
8% of body weight (mL) for plasma or was the total weight of every
tissue (g) for tissues; Mdose was the injection dosage (mg/kg); W was
the weight of every animal (kg).
The results were shown in Figure 2. Data shown were
presented as mean+SD (n=6). The data revealed that the
percentage of honokiol amount in brain was relatively high
compared with other tissues and they were respective 0.3960.08
in brain, 0.12960.026 in heart, 0.5860.11 in liver, 0.0460.01 in
spleen, 1.3360.32 in lung, 0.3760.09 in kidney and 1.0960.08 in
plasma. It was proved indirectly that honokiol could cross BBB
into brain and kept a high amount in brain.
Growth Inhibition of Honokiol against 9L Gliosarcoma
and U251 Glioma Cells
The effects of presence or absence of honokiol on rat 9L
gliosarcoma and human U251 glioma cells proliferation for 24 h
were investigated. Honokiol reduced the rat 9L gliosarcoma and
human U251 glioma cells number with IC50 of 15.61 mg/mL and
16.38 mg/mL, respectively. Honokiol produced dose-dependent
inhibition of the growth of rat 9L gliosarcoma cells (Figure 3, A)
and human U251 glioma cells (Figure 3, C) in culture. Data were
expressed as mean 6 SD (n=3 at each dose).
Effect of Honokiol on Apoptosis in 9L Gliosarcoma and
U251 Glioma Cells
Apoptosis was measured using the sub-G1 DNA content
determined via flow cytometry. Cells in the sub-G1 phase were
considered to be apoptotic. The apoptosis rates were respectively
30.2163.98% and 29.3664.51% in rat 9L gliosarcoma cells
(Figure 3, B) and human U251 glioma cells (Figure 3, D) when
treated with 16 mg/mL honokiol for 24 h. Data were expressed as
mean 6 SD (n=3).
Effect of Honokiol on the Growth of 9L Gliosarcoma and
U251 Glioma
In rat 9L intracerebral gliosarcoma model, the tumor volumes
and MRI images were measured every 4 days for 22 days by 3-T
unit MRI. The tumor volume and some representative MRI
images were indicated in Figure 4, A. Data shown were presented
as mean 6 SD of six animals per group (*, P,0.05; **, P,0.01).
There was no statistical difference between vehicle group
(2.5261.46 mm
3) and honokiol group (2.3661.39 mm
3) at 10-
day treatment in tumor volumes. However, after 14-day of initiate
treatment, honokiol had begun to present the capability of
inhibiting the growth of 9L tumor (18.2864.92 mm
3) as compared
with the vehicle group (43.9265.07 mm
3)( P=0.000). After18-day
of initiate therapy, tumor volumes in honokiol group rats were
68.9566.52 mm
3 versus 125.70611.58 mm
3 in vehicle group rats
(P=0.000), with 45.15% inhibiting rate of tumor volume. After
22-day of initiate treatment, honokiol group rats showed
significantly lower tumor volumes (112.70610.16 mm
3) compared
with vehicle group rats (238.63619.69 mm
3)( P=0.000), with
52.77% inhibiting rate of tumor volume. At this time, all of the rats
in vehicle group had large tumor volumes close to 250 mm
3. The
results demonstrated that honokiol was effective to inhibit tumor
growth in rat 9L intracerebral gliosarcoma model.
In human U251 xenograft glioma model, the tumor volumes of
nude mice were measured every 3 days for 27 days. The tumor volume
were shown in Figure 4, B. Data shown were presented as mean 6
SD of six animals per group (*, P,0.05; **, P,0.01). There were
statistical differences between vehicle group and honokiol group after
18-day treatment in tumor volumes. The data of honokiol group versus
vehicle group were respectively 318.336105.05 mm
3 versus
473.526109.15 mm
3 for 18-day of initiate treatment (P=0.031),
615.026124.10 mm
3 versus 1034.816279.58 mm
3 for 21-day
(P=0.012), 850.326107.78 mm
3 versus 1527.206365.42 mm
3 for
24-day (P=0.004) and 1450.836348.36 mm
3 versus 2914.176
780.52 mm
3 for 27-day (P=0.002) with 50.21% inhibiting rate of
tumor volume.
















Mean 41.37 9.30 262.28 285.99 40.74 4.18 0.07
SD 2.93 0.48 19.71 20.47 3.19 0.27 0.00
doi:10.1371/journal.pone.0018490.t001
Table 2. Determined amount of honokiol in cerebrospinal
fluid and brain at four time points after drug administration
(n=6 per time point).
Concentration (mean ± SD)
5 min 30 min 60 min 120 min
Cerebrospinal
fluid (mg/mL)
1.05960.087 0.60260.011 0.09560.003 0.05360.005
Brain (mg/g) 11.9761.09 6.1360.32 2.6960.57 1.4760.38
(Ccsf/Cp)6100 (%) 11.39% 24.98% 9.05% 9.81%
doi:10.1371/journal.pone.0018490.t002
Table 3. Mean brain and plasma concentration of honokiol in
rat after intravenous administration of 20 mg/kg (n=6).
5 min 30 min 60 min 120 min
Plasma (mg/mL) 9.30 2.41 1.05 0.54
Brain (mg/g) 11.97 6.13 2.69 1.47
Cb/Cp (ratio) 1.29 2.54 2.56 2.72
doi:10.1371/journal.pone.0018490.t003
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doi:10.1371/journal.pone.0018490.g002
Figure 3. Honokiol inhibited the growth and induced apoptosis in rat 9L gliosarcoma and human U251 glioma cells. A and C, Dose-
dependent inhibition of 9L gliosarcoma and U251 glioma cells growth, respectively: cells were exposed to various doses of honokiol for 24 h; B and D,
Apoptosis of 9L gliosarcoma and U251 glioma cells, respectively: cells were treated with 16 mg/mL honokiol for 24 h.
doi:10.1371/journal.pone.0018490.g003
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and U251 Glioma
In rat 9L intracerebral gliosarcoma model, survival of rats in
honokiol group was prolonged compared with that in vehicle
group, and the mean survival time in honokiol group were
33.6761.76 days post tumor implantation, however, 28.6761.59
days in vehicle group. All rats in vehicle group died or their tumor
volume increased to 250 mm
3 at 33 days after 9L cells
implantation. In contrast, honokiol treated group resulted in a
significant increase in life span (P,0.05, by log rank test) and 50%
rats survived at 33 days (Figure 5, A). Data shown were presented
as mean 6 SD of six animals per group. The 5-day growth delay
observed for this very aggressive tumor was exciting and highly
significant in light of the dismal prognosis of patients with brain
tumors, being equivalent to a bout 4-month extension in life for a
patient with a 1-year life expectancy [26,27]. The results
demonstrated that honokiol was effective to prolong survival time
in rat 9L intracerebral gliosarcoma model. These properties of
honokiol suggested additional investigation of its therapeutic
potential in gliosarcoma in the clinic.
In human U251 xenograft glioma model, honokiol could
prolong the survival of nude mice as the same above. Honokiol
group resulted in a significant increase in life span (P,0.05, by log
rank test) and 66.7% mice survived at 37 days, however, all mice
in vehicle group died or their tumor volume increased to
4000 mm
3 after U251 cells implantation at this time (Figure 5,
B). Data shown were presented as mean 6 SD of six animals per
group.
Inhibition of Angiogenesis
Angiogenesis within tumor tissues from human U251 glioma
xenograft nude mice was assessed in tumor sections stained with
an antibody reactive to CD31 and quantified as described in
Materials and Methods. The results were shown in Figure 6.
Compared to vehicle group, honokiol group resulted in apparent
inhibition of angiogenesis in tumors. The numbers of blood vessels
treated with vehicle and honokiol were 58.669.1 and 29.162.3,
respectively.
Figure 4. Honokiol decreased rat 9L intracerebral tumor and human U251 glioma growth in vivo. A for rat 9L gliosarcoma model; B for
human U251 glioma xenograft model (*, P,0.05; **, P,0.01).
doi:10.1371/journal.pone.0018490.g004
Figure 5. Honokiol prolonged the survival time of 9L
intracerebral gliosarcoma rats and human U251 glioma
xenograft nude mice. A for rat 9L gliosarcoma model; B for human
U251 glioma xenograft model.
doi:10.1371/journal.pone.0018490.g005
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Toxicity of honokiol was evaluated in rats by intravenous
administration with low-dose, middle-dose and high-dose once a
day for 14 days. Body weight, mean daily food intake,
hematological values, serum biochemical values and tissue
pathologic changes of rats were investigated. The results showed
that no significant differences were observed in body weight
(Table 4), mean daily food intake(Table 5) hematological
values(Table 6), serum biochemical values (Table 7) and tissue
pathologic changes (Figure 7) between honokiol-individual dose
and vehicle group. There were also no significant honokiol-dose-
related differences.
Discussion
In this study, we had investigated whether honokiol could cross
the BBB and BCSFB for the first time. The mean amount of
honokiol in brain and CSF ranged from 11.97 to 1.47 mg/g and
from 1.059 to 0.053 mg/mL, respectively. The amount of honokiol
in brain and CSF changed up and down along with that in plasma.
About 10% of honokiol amount in plasma crossed BCSFB into
CSF. The BBB permeability of honokiol was measured by the
ratio of Cb/Cp. We found that the ratios of Cb/Cp reached
immediately the max value at 30 min post administration and kept
a steady-state level after 30 min. The level was 2,3. In fact, most
of anti-tumor drugs including paclitaxel were difficult to cross BBB
and the ratio of Cb/Cp was further less than 0.2 [28]. Our results
demonstrated that honokiol had the preferable abilities of BBB
and BCSFB penetrations, and the abilities may contribute to its
suitable lipophilicity when honokiol was transported by passive
diffusion, or its specific transport mechanisms when honokiol was
transported by transporter. If honokiol was transported by
transporter, the binding between membrane transport protein
and honokiol would do not achieve saturation at the beginning of
time. When the binding achieved saturation, the transport ability
of membrane transport protein would keep balance. Therefore,
the ratios of Cb/Cp kept a steady-state level after 30 min.
The results of comparison of honokiol distribution in plasma,
brain and other tissues showed that the order of percentage of
honokiol amount was followings: lung.plasma.liver.brain.
kidney.heart.spleen. The percentage ratios of lung to brain and
liver to brain were respectively about 3.41–fold (1.33/0.39) and
1.49–fold (0.58/0.39). And the percentage value in brain was
higher compared to other tissues. It was a surprise finding that the
percentage value in brain was high and was close to that in liver
which was the largest internal organ. Meanwhile, the results
suggested that honokiol might possess a potential therapeutically
strategy against liver cancer and lung cancer except brain cancer.
In addition, in previous study the distribution of cisplatin, as one of
malignant gliomas treatment drugs, showed that cisplatin
accumulated mainly in kidney, liver, lung and heart [29]. From
the above results, we could gain a conclusion that the two drugs,
whether honokiol or cisplatin, mainly accumulated in lung, liver
and kidney. The reasons might be summarized as follows: 1). Lung
had a spongy texture and was honeycombed with epithelium
having a much larger surface area in total than the outer surface
area of the lung itself, which might make large quantities of drugs
accumulate in lung. 2). Capillaries were the smallest, but most
abundant blood vessels, where the exchange of gases between the
blood and the tissues occured. The more capillaries around tissues
were, the more amounts of drugs in tissues might be. Tissues such
as liver and kidney had extensive capillary network, therefore, it
might make large quantities of drugs accumulate in liver and
kidney. The difference between honokiol and cisplatin in
biodistribution was that the percentage value of honokiol amount
in brain, which also had extensively specific capillary network
named BBB and BCSFB, was high, however, the percentage value
of cisplatin amount in brain was few. It might be concerned with
abilities of crossing BBB and BCSFB of drugs.
Figure 6. Tumor angiogenesis from human U251 glioma
xenograft nude mice was assessed using immunohistochemi-
cal staining with anti-CD31 antibody. Microvessel counting was
performed at 2006. Significantly reduced numbers of blood vessels in
tumors treated with honokiol in comparison with vehicle. Data
represented the mean 6 SD of microvessels per high-power field
(*, P,0.05 vs. vehicle).
doi:10.1371/journal.pone.0018490.g006
Table 4. The effect of intravenous administration with vehicle or honokiol on the body weight of rats and data represented the
mean 6 SD (n=5), the unit was g.
Time Vehicle Honokiol(20 mg/kg) Honokiol(40 mg/kg) Honokiol(80 mg/kg)
Day 0 169.165.3 167.864.9 174.164.2 168.763.6
Day 2 178.367.4 176.168.3 179.265.7 175.964.7
Day 6 205.569.4 199.5610.3 210.469.8 216.5610.2
Day 9 235.1612.6 226.3612.1 229.8611.5 231.6613.7
Day 13 271.9613.2 261.3614.7 280.4613.6 269.2615.1
Day 15 255.3612.9 249.8615.2 263.1614.2 251.7615.8
doi:10.1371/journal.pone.0018490.t004
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aggressive tumor cells of the central nervous system [27,30].
Previous studies had shown that mean survival of patients with
malignant gliomas (glioblastoma multiforme or gliosarcoma) after
surgery and radiotherapy was approximately 10 months, and
chemotherapy had been relatively ineffective in extending survival
due to their poor penetration through the BBB and BCSFB [31].
Cisplatin, as one of cytotoxic drugs, had only weak effect in rat 9L
gliosarcoma model. However, cisplatin in combination with
antiangiogenic agent thalidomide improved the treatment efficacy
for the intracranial tumors, and increased the survival time from
18 days for the untreated controls to 20.5 days [29]. Dexameth-
asone, as a glucocorticoid hormone and antiangiogenic agent,
could decrease tumor volume compared to control group with
about 60% maximum inhibiting rate in rat 9L intracerebral
gliosarcoma model [32]. In our study, an orthotopic rat 9L
intracerebral gliosarcoma model and human U251 xenograft
glioma model were established to evaluate the efficacy of honokiol
via intravenous administration. The results revealed that honokiol
was an antiangiogenic agent and could well contribute anti-tumor
activity by inhibiting tumor growth and prolonging survival time.
Honokiol significantly reduced tumor volume with high inhibiting
rate and significantly improved the survival time compared to
vehicle group.
Due to the existence of specific efflux transporters, brain tumors
are easy to be resistant to chemotherapy. P-glycoprotein played an
important role in restricting access of substrate drugs across the
BBB in to brain [33,34]. Previous studies have proved that some
anti-tumor drugs including vincristine and cyclosporine A have the
low BBB and BCSFB penetration into brain ascribe to the
existence of P-glycoprotein [33,35]. Therefore, it is urgent to
develop a chemotherapy agent of brain tumor without resulting in
resistance. The high Cb/Cp ratios and good orthotopic anti-
gliosarcoma activity of honokiol suggested that honokiol might
have the abilities to escape the effect of P-glycoprotein and cross
BBB into brain, and contribute to the anti-tumor activity in brain




This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by our Institutional Animal Care and Use
Committee of the Sichuan University in China (Permit Number:
Table 5. The effect of intravenous administration with vehicle
or honokiol on the mean daily food intake of rats and data








Day 2 21.8 20.7 21.5 22.1
Day 9 25.3 26.6 24.9 24.6
Day 13 27.1 27.9 28.0 27.6
doi:10.1371/journal.pone.0018490.t005
Table 6. The effect of intravenous administration with vehicle or honokiol on hematology of rats and data represented the mean
6 SD (n=5).
Parameter Vehicle Honokiol(20 mg/kg) Honokiol(40 mg/kg) Honokiol(80 mg/kg)
WBC (10
9/L) 3.6460.71 3.5660.78 4.0361.11 3.7361.21
NEU (10
9/L) 0.29960.118 0.34260.213 0.35660.181 0.37160.180
LYM (10
9/L) 3.3260.61 3.1160.86 3.5561.02 3.4361.03
MONO (10
9/L) 0.04260.023 0.03960.023 0.04660.031 0.04860.029
EOS (10
9/L) 0.03260.011 0.03160.015 0.03460.015 0.02960.011
BASO (10
9/L) 0.00360.004 0.00360.001 0.00560.006 0.00560.003
NEU% (%) 8.7261.98 10.0164.31 9.8963.92 9.9163.92
LYM% (%) 90.162.7 88.665.7 88.565.6 88.965.2
MONO% (%) 1.35860.586 1.13760.962 1.80161.972 1.15360.881
EOS% (%) 0.84160.139 0.85160.314 0.87160.367 0.72460.286
BASO% (%) 0.12060.075 0.09560.085 0.15360.089 0.12760.080
RBC (10
12/L) 6.3660.39 6.6160.38 6.4160.29 6.2860.22
HGB (g/L) 138691 3 1 681 3 5 66 12868
HCT (%) 41.261.3 41.361.4 41.261.5 40.961.3
MCV (fL) 64.661.9 64.162.1 64.061.8 64.261.6
MCH (pg) 20.860.8 20.860.7 20.560.6 20.760.7
MCHC (g/L) 324653 2 2 663 2 1 68 32067
RET (%) 3.5660.91 3.6360.87 3.4360.92 3.4960.69
PLT (10
9/L) 11346123 1143698 11616126 11506172
PT (sec) 8.260.4 8.160.5 8.260.2 8.260.2
APTT (sec) 17.261.5 17.361.9 17.261.5 17.161.6
doi:10.1371/journal.pone.0018490.t006
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anesthesia, and all efforts were made to minimize suffering.
Reagents, Animals, Cell Line and Cell Culture
Honokiol (purity $98%) was separated and purified in our
laboratory, as reported previously [36]. The lipopolysaccharide
(LPS) contamination of honokiol was directly confirmed by
Limulus Amebocyte Lysate (LAL) test and the value was less than
0.25 EU per mg of honokiol. Diphenyl (purity $99%, internal
standard) was purchased from the National Institute for the
Control of Pharmaceuticals and Biological Products (Chengdu,
China). All chemicals and solvents were American Chemical
Society (ACS) analytical grade or HPLC grade. Male Sprague-
Dawley rats (8,10 weeks old, 220,260 g, n=30) and male
Sprague-Dawley rats (5,6 weeks old, 160,180 g, n=20) were
obtained from the Laboratory Animal Center of Sichuan
University in China. Male Fisher 344 rats (200,220 g, n=12)
and female athymic nude mice (6,8 weeks old, 18,22 g, n=24)
were purchased from the Animal Institute of the Chinese Medical
Academy (Beijing, China).
The rat 9L gliosarcoma and human U251 glioma cell lines were
purchased from American Type Culture Collection (Rockville,
MD, USA) and passaged in our laboratory for about 2 months
after receipt. Cells were cultured in DMEM supplemented with
10% heat-inactivated fetal calf serum, penicillin (10 IU/mL),
streptomycin (10 mg/mL) and 10% nonessential amino acids, and
maintained at 37uC in a humidified incubator containing 5% CO2
and harvested by trypsinization at 70% to 80% confluence in log-
phase growth on the day of tumor injection (day 0).
Measurement of Honokiol Amount After Intravenous
Administration in Plasma
Male Sprague-Dawley rats ((8,10 weeks old, 220,260 g, n=6)
were anesthetized with chloral hydrate and then a polyethylene
tube (0.28 mm, I.D., 0.61 mm, O.D.) was inserted into the right
femoral artery of rat. The rats were placed in cages and allowed to
Table 7. The effect of intravenous administration with vehicle or honokiol on serum biochemistry of rats and data represented the
mean 6 SD (n=5).
Parameter vehicle Honokiol(20 mg/kg) Honokiol(40 mg/kg) Honokiol(80 mg/kg)
ALP (U/L) 171.3665.1 159.2670.9 149.8659.8 160.1663.9
ALT (U/L) 43.968.2 44.966.7 45.965.2 45.566.3
AST (U/L) 112.8617.5 118.6620.2 113.9618.4 112.3619.2
CK (U/L) 5716189 5676169 5526187 4986195
Urea (mmol/L) 5.0160.91 4.7160.67 4.5561.01 4.7360.96
Crea (mmol/L) 16.361.8 15.961.2 15.661.7 16.061.9
TP (g/L) 56.561.9 56.162.2 56.962.3 57.062.8
ALB (g/L) 40.261.6 40.161.7 41.261.6 41.362.0
A/G 2.6060.65 2.5160.41 2.6060.41 2.4960.71
GLU(mmol/L) 6.3160.76 6.4260.87 6.2560.52 6.6860.56
TBIL (mmol/L) 2.060.7 2.160.6 1.960.8 1.860.8
CHOL (mmol/L) 1.4160.23 1.4260.25 1.4160.49 1.4260.36
TG (mmol/L) 0.4660.36 0.3960.26 0.4160.25 0.4060.28
K
+ (mmol/L) 3.9960.43 3.9160.18 3.8760.28 4.0360.85
Na
+ (mmol/L) 139.261.5 138.962.1 139.861.8 140.261.9
Cl
2 (mmol/L) 100.361.5 99.861.7 100.161.1 99.662.0
doi:10.1371/journal.pone.0018490.t007
Figure 7. Histological staining of organs of rats with vehicle and high-dose honokiol. Rats were injected via caudal vein at a dose of
80 mg/kg body weight once a day for 14 days.
doi:10.1371/journal.pone.0018490.g007
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in mixture of polyethoxylated castor oil and ethanol (1:1, v/v) was
administered to the rats at a single dose of 20 mg/kg body weight
(concentration of honokiol: 4 mg/mL; injected volume of solution
per rat: 1.1,1.3 mL) via caudal vein. Then about 0.20 mL of
blood samples were collected through the cannulated tube at
designated time for 0, 5 min, 10 min, 15 min, 30 min, 45 min,
1 h, 1.5 h and 2 h into tubes containing heparin sodium. After
2 h, the rats were euthanized via CO2 asphyxiation. Plasma
samples were obtained after immediate centrifugation of blood at
3000 rpm for 10 min at 4uC. Plasma samples were prepared as
described previously [37]. Diphenyl was selected as internal
standard and 10 mL of prepared samples was directly injected into
HPLC system for analysis.
Perfusion Method
The honokiol was also administered to other male Sprague-
Dawley rats ((8,10 weeks old, 220,260 g, n=24) at a single dose
of 20 mg/kg body weight via caudal vein. The time for respective
5 min, 30 min, 60 min and 120 min (Six rats per time point) post
administration was designated to collect the cerebrospinal fluid
(CSF), brain and other tissues after cardiac perfusion through left
ventricle using the perfusion method described previously [38] to
determinate exactly the amount of honokiol. Rats were perfused
with Krebs-Henseleit buffer (118 mM NaCl, 14.7 mM KCl,
2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4,2 5 m M
NaHCO3, 10 mM D-glucose, pH 7.4) containing heparin (5 U/
mL). This buffer was bubbled with a mixture of 95% O2 and 5%
CO2, filtered through Millex HV filter (Millipore, Bedford, MA),
incubated for about 30 min on ice. Peristaltic pump speed was set
at 30 mL/min and time taken for perfusion was 5 min.
Evaluation of BBB and BCSFB Penetration of Honokiol in
Vivo
Following perfusion, the rats were immediately mounted in a
ligneous device. The back of the neck and base of the skull were
shaved and disinfected with 70% ethyl alcohol. A midline incision
was made beginning at between the ears and ending approxi-
mately 2 cm caudally. The fascia was retracted and superficial
muscles were dissected. A retractor was placed with the spring side
pointing in rostral direction. Separation of the superficial muscles
exposed an underlying layer of muscles which could be easily
separated along the midline by blunt dissection, exposing the
atlanto-occipital membrane. In order to gain better access to the
atlanto-occipital membrane, the incisor bar was lowered on the
animal’s head, inducing a downward curvature of about 45uC
from horizontal. A small slit was made along the midline of the
membrane and the incision was then enlarged to expose the
underlying dura mater. Immediately a needle attached to 1 mL
syringe was carefully inserted at a 30u angle to the dura, from the
caudal end of the incision. The needle was inserted with the bevel
of the needle faced up initially. When the bevel was covered by the
dura, the needle was then gently shifted so that the angle of
insertion was parallel with the dura and the bevel was turned away
from the dura. Once parallel with the dura, the needle was
inserted approximately 1 mm farther beneath the dura to ensure
that it did not come out during CSF collection. Positioning of the
needle was chosen to prevent damage of vasculature on the pia.
Finally, aspiration of CSF was achieved by pulling back the syringe
plunger, which was completed in less than 1 min. The operation
was shown in Figure 8. Approximately 0.1 mL of CSF was
obtained and stored at 280uC until analysis by HPLC. The rats
were then decapitated and forebrains of the rats were separated
from the cerebellum and medulla oblongata. After removal of the
pia mater and choroid plexus, the brains of rats were collected,
lightly blotted to remove any excess fluid, weighted and stored at
280uC until analysis by HPLC.
Brain samples were weighed accurately and homogenized in
PBS (pH 7.4, 250 mg/mL). The analytical process of CSF and
brain homogenized samples kept the same as that of plasma
samples. Dissimilarly, the volume (1 mL) of brain homogenized
samples was 10-fold compared to plasma samples (0.1 mL).
Honokiol Amount Taken Up by Other Tissues
Similar to the described above, after brains were collected,
heart, liver, spleen, lung and kidney were also collected at 30 min
time point. The analytical process of these tissues samples kept the
similar to that of brain samples (Some lung samples needed to be
diluted).
HPLC Analysis
Chromatographic analyses were performed with an Alliance
2965 HPLC system (Waters, Milford, MA, USA) consisting of a
column heater and an autosampler, and detection was carried out
by using UV detector at 209 nm. Chromatographic separation of
honokiol was carried out on a reversed-phase column (Atlantis
C18 column, 15064.6 mm, 5 mm, Waters). The column temper-
ature was maintained at 28uC. Samples were eluted using
acetonitrile and water (60:40, V/V) at a flow rate of 1.0 mL/min.
Growth Inhibition Assays
In vitro growth inhibition of honokiol for rat 9L gliosarcoma
and human U251 glioma cells was assessed using an MTT assay.
Briefly, cells were seeded in a 96-well plate at a plating density of
5610
4/mL and cultured for 24 h to allow them to adhere to the
plate. Harvested cells were exposed in presence or absence with
different concentrations of honokiol (0,32 mg/mL) in fresh
DMEM medium. The plates were placed at 37uC for 24 h. Then
cells were added to 20 mL of MTT (5 mg/mL) and cultured for
3 h at 37uC. The supernatant was removed, the plate was
reloaded with 150 mL of DMSO, and the absorbance was
measured at 570 nm using a Spectramax M5 Microtiter Plate
Luminometer (Molecular Devices). The absorbance value of
untreated cells was considered to be 100%. IC50 was defined by
the concentration that caused a 50% absorbance decrease in
treated cells compared with untreated cells. Three replicates of
each well for each treatment dose were performed.
Assessment of Apoptosis by Flow Cytometry
To quantitative assessment of apoptosis, flow cytometric
analysis was applied to identify sub-G1 cells/apoptotic cells and
measure the percentage of sub-G1 cells. Rat 9L gliosarcoma and
human U251 glioma cells were seeded in a 6-well plate and treated
with physiological saline and honokiol (16 mg/mL, about IC50) for
24 h, respectively. Then cells were collected, washed with PBS,
and suspended in 1 mL hypotonic fluorochrome solution contain-
ing 50 mg of propidium iodide/mL in 0.1% sodium citrate plus
0.1% Triton X-100. The cells were analyzed using a flow
cytometer (ESP Elite, Beckman-Coulter, Miami, FL). The
numbers of apoptotic cells appearing in the cell cycle distribution
were estimated using Listmode software. The experiments were
repeated thrice.
Intracerebral Tumor Model and Xenograft Tumor Model
The orthotopic intracerebral gliosarcoma model was established
to evaluate directly the efficacy and assess indirectly the blood-
brain barrier penetration of honokiol as described previously
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the orthotopic gliosarcoma allograft was generated by intracere-
bral injection of rat 9L cells (5610
4 cells in 10 ml serum-free
DMEM). The heads of the rats were immobilized in a stereotactic
frame, shaved and disinfected with 10% povidone iodine. After a
midsagittal scalp incision to expose the skull, a small burr hole was
drilled at 3 mm to the right of the sagittal suture and 1 mm
anterior to the coronal suture. A 10-gauge needle connected to a
microsyringe was attached to a stereotactic manipulator. The
needle was inserted into a depth of 5 mm under cerebral dura
mater, and then the cell suspension was injected into the caudatum
slowly over a 5-min period. The needle was left in this place for
5 min to allow for diffusion before slow withdrawal. The burr hole
in the skull was sealed with sterile bone wax and the incision was
closed.
The human U251 xenograft glioma model was also established
to further prove the efficacy of honokiol as described previously
[43,44]. The human U251 glioma cells (5610
5 cells) were injected
s.c. into the right flanks of athymic nude mice (n=24).
Assessment of Anti-Tumor Activity in Vivo
The orthotopic intracerebral tumor rats were randomly and
equally divided into two groups (6 rats for each group) when 9L
cells were stereotactic injected for seven days. The first group
(vehicle group) was injected via caudal vein with vehicle solution
consisting of 2.5% mixture of Cremophor EL and ethanol in 5%
dextrose. The second group (honokiol group) was injected via
caudal vein with honokiol (dissolved in vehicle solution) at a dose
of 20 mg/kg body weight (concentration of honokiol: 4 mg/mL;
injected volume of solution per rat: 1.0,1.1 mL). Each group was
given treatment twice per week for 3 weeks. Tumor volume was
measured and calculated by 3-T unit magnetic resonance imaging
(MRI) in West China Hospital (Chengdu, China) according to the
area of tumor in each MR image slice every 4 days for 22 days. We
examined the animals daily for survival until 40 days and scored
them as dead when tumor volume increased to 250 mm
3. The rats
without death were euthanized via CO2 asphyxiation.
The xenograft U251 glioma nude mice were also randomly and
equally divided into vehicle group and honokiol group (12 mice for
each group) when tumors were palpable (about 30 mm
3). Each
group was given treatment via caudal vein administration twice
per week for 3 weeks similar to the dosage and method above.
Tumor volume was measured every three days with a caliper and
calculated using the following formula: 0.5236length6width
2. Six
mice in each group were decapitated on the 27th day. Tumor,
heart, liver, spleen, lung, kidney and brain were excised and fixed
in 4% paraformaldehyde. Other six mice in each group were
examined daily for survival until 45 days and scored as dead when
tumor volume reached 4000 mm
3. The mice without death were
euthanized via CO2 asphyxiation.
Immunohistochemistry for Microvessel
Tumor tissues from human U251 glioma xenograft nude mice
at the end of treatments were paraffin embedded, cut into 4-mm
sections, and stained using rabbit monoclonal antibody against
mouse marker CD31 (BD Biosciences Pharmingen, San Diego,
CA) to investigate the anti-angiogenesis activity of honokiol. The
vessel density was determined by counting the number of
microvessels per one high-power field [23].
Evaluation of Toxicity
The toxicity evaluation of honokiol was performed as previously
described with some modifications [45]. Male Sprague-Dawley
rats (5,6 weeks old, 160,180 g, n=20) were divided into four
groups (5 rats in each group): vehicle group, low-dose group
(20 mg/kg body weight), middle-dose group (40 mg/kg body
weight) and high-dose group (80 mg/kg body weight). The rats
were housed in individual wire cages in each group and
administrated via caudal vein with vehicle or honokiol once a
day for 14 days. During the experiment, body weight of every rat
was measured at the 0 day, 2th day, 6th day, 9th day and 13th
day. After the 14th administration, the rats were banned diet for
12 h and body weight of every rat was again measured at the15th
day. The total food intake in each cage (each group) was measured
at the 2th day, 9th day and 13th day during 24 h via weight loss
method, respectively. And the mean daily food intake fo rat in
each cage (5 rats in each cage) was calculated by averaging
method. At the 15th day, all rats were anesthetized and sacrificed.
Figure 8. Collection of CSF from cisterna magna with a rat.
doi:10.1371/journal.pone.0018490.g008
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10 min), and then plasma samples were analyzed for homatolo-
gical test including WBC (white blood cell count), NEU (number
of neutrophils), NEU% (percent of neutrophils), LYM (number of
lymphocytes), LYM% (percent of lymphocytes), MONO (number
of monocytes), MONO% (percent of monocytes), EOS (number of
eosinophils), EOS% (percent of eosinophils), BASO (number of
basophils), BASO% (percent of basophils), RBC (red blood cell
count), HGB (hemoglobin), HCT (hematocrit), MCV (mean
corpuscular volume), MCH (mean corpuscular hemoglobin),
MCHC (mean corpuscular hemoglobin concentration), RET
(reticulocyte count), PLT (platelet count) using a blood cell
counter (Hemavet 0950, CDC Technology, Irvine, CA), PT
(prothrombin time), APTT (activated partial thromboplastin time)
using a Coagulometer ACL 100 (Instrumentation Laboratory Co,
Lexington, KY, USA). Serum samples were also obtained and
examined for biochemical test including ALB (albumin), ALP
(alkaline phosphatase), AST (aspartate aminotransferase), ALT
(alanine aminotransferase), CHOL (cholesterol), Urea (blood urea-
N), Crea (creatinine), GLU (glucose), TP (total protein), TBIL
(total bilirubin), CK (creatine phosphokinase), Na (sodium),
K(potassium), Cl (chloride), TG (triglyceride), and A/G (ratio of
albumin to globulin) using a biochemical blood analyzer (Hitachi
7180, Hitachi, Japan). Tissues of heart, liver, spleen, lung, kidney
and brain (cerebellum) were also collected and embedded in
paraffin, cut into 4-mm sections for H&E staining.
Statistical Analysis
The concentration-time data of honokiol was fitted by the Drug
and Statistics (DAS) software, version 2.1.1, edited and published
by the Mathematical Pharmacology Professional Committee of
China. All statistical data were analyzed using the SPSS 13.0
software. Statistical comparisons were made with one-factor
analysis of variance (ANOVA). For the survival time of animals,
Kaplan-Meier curves were established for each group, and the
survivals were compared by means of the log rank test. Student’s t-
test was used to calculate probability (P) values. In all test a P value
of ,0.05 was regarded as statistically significant. Experiments
were performed at least in triplicate.
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